Skip to main content

Abcellera Biologics Inc (ABCL) Stock

Abcellera Biologics Inc Stock Details, Movements and Public Alerts

Stock Details

Abcellera Biologics Inc (ABCL), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $3.82. Over the past 52 weeks, it has ranged between $1.89 and $6.51. This places the current price at 58.7% of its 52-week high and 102.0% above its 52-week low. Recent trading volume was recorded at 2,989,380. The 14-day Relative Strength Index (RSI) stands at 28.50, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $5.09 by 24.95%. Similarly, it is above its 200-day moving average of $3.60 by 6.11%. The MACD histogram is -0.21, indicating bearish momentum (MACD Line: -0.20, Signal Line: 0.01). There are currently 3 active alerts set for ABCL by users.

52-Week Range

$6.51 - $1.89

-41.32% from high · +102.01% from low

Avg Daily Volume

4,877,342

20-day average

100-day avg: 5,768,957

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

27.47

Price to Book

1.77

EV/EBITDA

5.30

EPS (TTM)

-$0.56

Price to Sales

50.45

Beta

0.69

Less volatile than market

How is ABCL valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is ABCL's risk profile compared to the market?
With a beta of 0.69, Abcellera Biologics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.77 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-290.20%

EBITDA

$-218,379,008

Return on Equity

-15.60%

Return on Assets

-11.00%

Revenue Growth (YoY)

133.30%

Earnings Growth (YoY)

45.90%

How profitable and efficient is ABCL's business model?
0 The operating margin of -290.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -15.60% and ROA at -11.00%, the company achieves moderate returns on invested capital.
What are ABCL's recent growth trends?
Abcellera Biologics Inc's revenue grew by 133.30% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 45.90% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$1.7B

Revenue (TTM)

$32.88M

Revenue/Share (TTM)

$0.11

Shares Outstanding

298.83M

Book Value/Share

$3.41

Asset Type

Common Stock

What is ABCL's market capitalization and position?
Abcellera Biologics Inc has a market capitalization of $1.7B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 298.83M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does ABCL's price compare to its book value?
Abcellera Biologics Inc's book value per share is $3.41, while the current stock price is $3.82, resulting in a price-to-book (P/B) ratio of 1.12. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$9.33

144.24% upside potential

Analyst Recommendations

Strong Buy

1

Buy

6

Hold

1

Sell

0

Strong Sell

0

How reliable are analyst predictions for ABCL?
8 analysts cover ABCL with 88% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $9.33 implies 144.2% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on ABCL?
Current analyst recommendations:1 Strong Buy, 6 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 2, 2025, 02:52 PM

Technical Indicators

RSI (14-day)

28.50

Oversold

50-Day Moving Average

$5.09

-24.95% below MA-50

200-Day Moving Average

$3.60

6.11% above MA-200

MACD Line

-0.20

MACD Signal

0.01

MACD Histogram

-0.21

Bearish

What does ABCL's RSI value tell investors?
The RSI (Relative Strength Index) for ABCL is currently 28.50, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
How should traders interpret ABCL's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.20 below the signal line at 0.01, with histogram at -0.21. This bearish crossover indicates downward pressure. The 50-day MA ($5.09) is above the 200-day MA ($3.60), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Nov 10, 2025, 09:21 AM

Active Alerts

Alert Condition
Earnings Announcement
Threshold
1 days
Created
Nov 10, 2025, 02:14 PM
Alert Condition
Forward P/E falls below
Threshold
25 x
Created
Nov 10, 2025, 02:14 PM
Alert Condition
RSI Threshold Cross
Threshold
30
Created
Nov 10, 2025, 02:14 PM

Stay Ahead of the Market with Abcellera Biologics Inc Alerts

Set up price alerts for Abcellera Biologics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.